MedTrace Logo

Pharmacokinetic Interaction Between AZD3480 and Donepezil

NCT00713765 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2014-08-15

No results posted yet for this study

Summary

The aims of this study are to 1) examine the effects of AZD3480 and donepezil on the blood concentrations of each other and 2) assess the safety and tolerability of the combined administration of AZD3480 with donepezil.

Conditions

Interventions

DRUG

AZD3480

18 total doses of 40 mg, on days 1-18

DRUG

Donepezil

One single dose of mg on day 5

Sponsors & Collaborators

Principal Investigators

  • Hans Göran Hårdemark · AstraZeneca R&D, Sodertalje, Sweden

  • Simon Constable · ICON Development Solutions, Manchester, UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713765 on ClinicalTrials.gov